IBI376
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Indolent Non-hodgkin Lymphoma
Conditions
Indolent Non-hodgkin Lymphoma
Trial Timeline
Apr 7, 2020 → Nov 21, 2023
NCT ID
NCT04298879About IBI376
IBI376 is a phase 2 stage product being developed by Innovent Biologics for Indolent Non-hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04298879. Target conditions include Indolent Non-hodgkin Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04298879 | Phase 2 | Completed |
Competing Products
15 competing products in Indolent Non-hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Linperlisib ； Rituximab | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| GP2013 | Novartis | Phase 1 | 33 |
| Ibrutinib + GA 101 | Roche | Phase 2 | 52 |
| Obinutuzumab + Bendamustine | Roche | Phase 2 | 52 |
| Placebo + Rituximab + Idelalisib | Gilead Sciences | Phase 3 | 76 |
| Idelalisib | Gilead Sciences | Phase 1/2 | 40 |
| Idelalisib + Rituximab + Bendamustine + Placebo | Gilead Sciences | Phase 3 | 76 |
| Idelalisib + Rituximab + Bendamustine + Ofatumumab + Fludarabine + Everolimus + Bortezomib + Chlorambucil + Lenalidomide | Gilead Sciences | Phase 1 | 32 |
| Copanlisib + Nivolumab + Rituximab | Bristol Myers Squibb | Phase 1 | 32 |
| SAR245409 | Sanofi | Phase 1 | 32 |
| Copanlisib (BAY80-6946) | Bayer | Pre-clinical | 20 |
| Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2 | Lundbeck | Phase 3 | 74 |
| Bezuclastinib | Cogent Biosciences | Pre-clinical | 20 |